TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02283801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Study: NCT02600195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based Practice for Improving Quality (EPIQ) method
Description: The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
Study: NCT01265511

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets given bid for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCY-635
Description: SCY-635 tablets, 300 mg bid for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys
Description: 180 ug prefilled syringe given once per week for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: 180 ug prefilled syringe given once per week for up to 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus
Description: tablets given bid for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: tablets given bid for up to 48 weeks
Study: NCT00656331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine and Hydrocholorothiazide
Description: Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine and Hydrocholorothiazide
Description: Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
Study: NCT00265109

Intervention type: DRUG
Group type: OTHER
Intervention: Levetiracetam
Description: The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
Study: NCT02174406

Intervention type: PROCEDURE
Intervention: breast ultrasound

Intervention type: PROCEDURE
Intervention: DBT (Full field digital mammography + tomosynthesis)
Study: NCT04065711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soliton's Rapid Acoustic Pulse (RAP)
Description: Treatment for the temporary improvement in the appearance of cellulite.
Study: NCT02365246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immunoadsorptions with an IgE-specific adsorption column
Description: immunoadsorptions
Study: NCT00372073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: seliciclib
Description: 1200 mg bid x 3 days every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1200 mg bid x 3 days every 2 weeks
Study: NCT02290821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT02395796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Pressure Waveform
Description: When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
Study: NCT02612428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD System
Description: An extracorporeal human hepatic cell-based liver treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Control)
Description: Standard medical treatment as defined by the protocol
Study: NCT02078674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)
Study: NCT03825016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Oral Diclofenac Sodium
Study: NCT02078674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant
Study: NCT03867097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV infusion
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iloprost Injection, for intravenous use
Description: Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
Study: NCT03493412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
Description: 5 mg/kg will be used as the dose of BH4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
Description: 5 mg/kg will be used as the dose of BH4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01103492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HALO90 Ablation catheter
Description: FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
Study: NCT04390841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Stimulator
Description: The subjects will receive the intracardiac electrophysiological examination, during which the subjects will be subject to diagnostic electrical stimulation by the Qubic Stim Cardiac Stimulator. The subjects will also receive the clinical follow-up visit after cardiac electrical stimulation until they are discharged from the hospital.
Study: NCT01817959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.The Investigational Product (IP) were to be administered as an add-on treatment for the immunosuppressant regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous infusion at a volume/rate matching active treatment.The placebo was to be administered as well as an add-on treatment for the immunosuppressant regimen.
Study: NCT01860950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
Study: NCT01041872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Astrazeneca plain
Description: Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Astrazeneca plus lidocaine
Description: Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
Study: NCT01896609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin in Arm 1
Description: Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin in Arm 1
Description: Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
Study: NCT01860950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Description: a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
Study: NCT02797171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by intravenous (IV) infusion
Study: NCT03335826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Description: Combined epidural-general anesthesia and postoperative epidural analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia and postoperative intravenous analgesia.
Study: NCT01860950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathodal tDCS
Description: a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
Study: NCT00923845

Intervention type: DRUG
Group type: OTHER
Intervention: Pentostatin
Description: Pentostatin: 2- 4mg/m\^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Description: Allogeneic Hematopoietic Stem Cell Transplant
Study: NCT05347329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tongkat Ali Maca Plus
Description: Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
Study: NCT02078674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant
Study: NCT05347329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tongkat Ali Maca Plus
Description: Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tongkat Ali Maca Plus
Description: Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
Study: NCT02541968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy (face-to-face)
Study: NCT02078674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Matrix-M1™ adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01266837

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: 10 mg p.o once daily
Study: NCT02990494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD
Description: Standard Internet-delivered behavioral weight loss
Study: NCT04406155

Intervention type: PROCEDURE
Intervention: 3D-RWC-TVS with bowel preparation
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.~Bowel preparation is based on a low-residue diet given in the two days before the examination and a rectal enema administered a few hours before the procedure.

Intervention type: PROCEDURE
Intervention: 3D-RWC-TVS without bowel preparation
Description: Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
Study: NCT02990494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT
Description: enhanced standard Internet-delivered behavioral weight loss program
Study: NCT02541968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-behavioral therapy
Description: With therapist support
Study: NCT02990494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMOTE
Description: enhanced standard Internet-delivered behavioral weight loss program
Study: NCT00923845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Th2 rapa cells
Description: Th2 rapa cell Transplantation
Study: NCT01757288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB-PACLITAXEL
Description: nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACLITAXEL
Study: NCT01273207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Inhalation Solution (CIS)
Description: CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
Study: NCT00923845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Lymphocyte Harvest
Description: Apheresis
Study: NCT04211506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled sleep
Description: Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment with controlled lighting and meals.
Study: NCT00923845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Induction Therapy
Description: Pentostatin and cyclophosphamide (PC) conditioning regimen.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: GVHD prophylaxis
Description: Short course of sirolimus plus maintenance therapy with sirolimus A.
Study: NCT02541968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive-behavioral therapy without therapist support
Study: NCT04678050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine/ propofol
Description: ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h
Study: NCT00923845

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Hematopoietic Stem Cell Harvest
Description: Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
Study: NCT03687606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin
Description: White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin
Description: White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
Study: NCT04393714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation after extraction
Description: atraumatic extraction followed by graft material insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation after extraction
Description: atraumatic extraction followed by graft material insertion
Study: NCT01665326

Intervention type: OTHER
Intervention: Observational
Description: This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
Study: NCT03687606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: White freeze-dried cake or powder with specification of 75IU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotropin
Description: White freeze-dried cake or powder with specification of 75IU.
Study: NCT03824704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily
Study: NCT02918357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 labeled PSMA-11 PET
Description: Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
Study: NCT03824704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV nivolumab will be administered once every 4 weeks
Study: NCT02897830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).